Advanced Filters
noise

spinal-cord-disorders Clinical Trials

A listing of spinal-cord-disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 585 clinical trials
K Karen Cornett

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence …

years of age All Phase N/A

French Register of Patients With Spinal Muscular Atrophy

The primary objectives of the study are to obtain clinically meaningful data on survival and outcomes of all the patients with spinal muscular atrophy (SMA) 5q types 1 through 4 (according to international classification), being followed in the reference centers of the disease in France between September 1, 2016 and …

years of age All Phase N/A
W Wan-Jin Chen, PhD

A Registered Cohort Study on SMA

Spinal muscular atrophy (SMA) is an autosomal recessive disease that causes progressive muscle wasting and weakness due to loss of motor neurons in the spinal cord. This is a registered cohort of spinal muscular atrophy (SMA) type I,II and III in China. This study will provide further insights into the …

1 - 70 years of age All Phase N/A
Y Yun-Hui Chou

Neonatal Spinal Muscular Atrophy (SMA) Screening

Parents or legal guardian of neonates who signed agreement will receive SMA screening test if their neonates are affected with SMA. The dried blood spots of routine newborn screening samples will be used to test if neonates have lost 2 copies of SMN1 gene. If neonates have positive SMA screening …

- 2 years of age All Phase N/A
D Danica Dragovic, MD

Spinal Muscular Atrophy Neonatal Screening Program

Spinal muscular atrophy (SMA) is a group of disorders caused by the degeneration of the motor neuron cells of the anterior horn of the spinal cord and, in some subtypes, of the bulbar motor neurons. Almost all cases are genetically determined. Most SMAs are autosomal recessive diseases, caused by homozygous …

48 - 72 years of age All Phase N/A

Adult SMA Research and Clinical Hub

Adult SMA REACH is a data collection study aiming to gain a better understanding of the impact of standards of care and new treatments on the natural history of Spinal Muscular Atrophy (SMA). This study is sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust. Adult SMA REACH is …

16 years of age All Phase N/A
Y Yi-Min Sun, M.D.

Hereditary Ataxia Research on Multi-Omics and Neuroclinical Insights in the Yangtze Delta

The goal of this observational study is to explore the clinical and genetic characteristics, multi-omics profiles, disease mechanisms, biomarkers, and potential therapeutic targets of hereditary ataxia (HA) in patients diagnosed with HA, primarily in the Yangtze River Delta region of China. The main questions it aims to answer are: What …

years of age All Phase N/A
Y Ying Gao, MD

China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine

A multi-center registration study of clinical characteristics of amyotrophic lateral sclerosis (ALS) patients with traditional Chinese medicine (TCM).

18 years of age All Phase N/A

Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)

Describe the distribution of ALS in mainland China, to explore the differences in the number of ALS in different times, regions and populations in order to further explore the causes affecting the distribution of ALS; To investigate the cause of ALS in mainland China in the crowd disease development process …

years of age All Phase N/A
S Sukrutha Thotala

Intermuscular Coherence as a Biomarker for ALS

The specific aims of this study are to: Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from …

20 - 90 years of age All Phase N/A

Simplify language using AI